Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3–5: Are They Robust? A Fragility Index Analysis
Abstract
Share and Cite
Capuano, I.; Buonanno, P.; Riccio, E.; Bianco, A.; Pisani, A. Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3–5: Are They Robust? A Fragility Index Analysis. J. Clin. Med. 2022, 11, 6184. https://doi.org/10.3390/jcm11206184
Capuano I, Buonanno P, Riccio E, Bianco A, Pisani A. Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3–5: Are They Robust? A Fragility Index Analysis. Journal of Clinical Medicine. 2022; 11(20):6184. https://doi.org/10.3390/jcm11206184
Chicago/Turabian StyleCapuano, Ivana, Pasquale Buonanno, Eleonora Riccio, Antonio Bianco, and Antonio Pisani. 2022. "Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3–5: Are They Robust? A Fragility Index Analysis" Journal of Clinical Medicine 11, no. 20: 6184. https://doi.org/10.3390/jcm11206184
APA StyleCapuano, I., Buonanno, P., Riccio, E., Bianco, A., & Pisani, A. (2022). Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3–5: Are They Robust? A Fragility Index Analysis. Journal of Clinical Medicine, 11(20), 6184. https://doi.org/10.3390/jcm11206184